What was the primary driver of IDEXX's revenue growth in the first nine months of 2025?

The primary driver of IDEXX's revenue growth was the strong performance in its Companion Animal Group (CAG) segment, which benefited from increased volumes and higher realized prices, particularly in IDEXX VetLab consumables and reference laboratory diagnostic services. Overall, CAG revenue increased by 9.3% year-over-year.

How did the company manage operating expenses and profitability in light of economic conditions?

IDEXX demonstrated effective management of operating expenses, with total operating expenses increasing by only 1.6% for the nine-month period despite significant revenue growth. This, combined with an increase in gross profit margin, led to a substantial 20.5% increase in income from operations and improved profitability. The company also benefited from certain one-time expense reductions, such as a decrease in general and administrative expenses related to a concluded litigation matter.

What is the company's liquidity position, and how is it managing its debt?

IDEXX maintains a strong liquidity position, with $208.2 million in cash and cash equivalents as of September 30, 2025. The company also has significant borrowing availability under its Credit Facility. Its debt management appears sound, with a consolidated leverage ratio of 0.65 (Debt to Adjusted EBITDA), well within the covenant limit of 3.5-to-1. The company successfully repaid its $250.0 million term loan and has plans to address its maturing 2025 Series B Notes.

How did foreign currency fluctuations impact the company's financial results?

For the nine months ended September 30, 2025, foreign currency exchange rates had a net positive impact on revenue, increasing it by approximately 0.4%. However, the overall impact on operating profit was relatively neutral, as hedge gains and losses, along with foreign currency transaction gains and losses, largely offset each other. The company continues to utilize hedging strategies to mitigate currency risks.

IDXX 10-Q Quarterly Report Q3 FY2025 — Revenue, Net Income, EPS

Summary

IDEXX Laboratories, Inc. reported strong financial results for the nine months ended September 30, 2025. Total revenue increased by 9.2% to $3.21 billion, driven by robust performance in its Companion Animal Group (CAG) segment, which saw a 9.3% revenue increase. The company demonstrated solid operational execution, with income from operations rising by 20.5% to $1.04 billion and net income growing by 20.8% to $811.3 million. Diluted EPS also saw a significant increase, reaching $9.99 for the nine-month period. The company's strategic focus on recurring revenue streams, particularly within its CAG Diagnostics recurring revenue category, continues to be a key driver of growth and profitability, with this segment showing a 7.8% increase. Financial health remains strong, with ample liquidity and a healthy balance sheet, supported by consistent operating cash flow generation. The company also continued its commitment to shareholder returns through active share repurchase programs. For the third quarter of 2025, IDEXX maintained its positive momentum, with total revenue up 13.3% year-over-year to $1.11 billion, and income from operations increasing by 16.8% to $354.8 million. The CAG segment once again led the growth, with a 13.5% revenue increase, bolstered by strong performance in IDEXX VetLab consumables and reference laboratory diagnostic services. Despite inflationary pressures and the impact of foreign currency fluctuations, IDEXX successfully expanded its gross profit margin and maintained disciplined operating expense management, leading to improved profitability. The company's outlook for the remainder of the year appears positive, with favorable currency impacts projected.

Financial Highlights

53 data points

Beta

Revenue

$1.11B

0.6% Gross Margin

Net Income

$274.61M

0.2% Net Margin

EPS (Diluted)

$3.40

Total Assets

$3.39B

Cash & Equivalents

$208.17M

Free Cash Flow

$371.23M

Financial Statements

Beta

Revenue	$1.11B
Cost of Revenue	$421.88M
Gross Profit	$683.35M
R&D Expenses	$63.41M
Operating Expenses	$328.51M
Operating Income	$354.85M
Net Income	$274.61M
EPS (Basic)	$3.43
EPS (Diluted)	$3.40
Shares Outstanding (Basic)	80.10M
Shares Outstanding (Diluted)	80.67M

Key Highlights

1Total revenue for the nine months ended September 30, 2025, increased by 9.2% to $3.21 billion, compared to $2.94 billion in the prior year.
2Companion Animal Group (CAG) revenue grew by 9.3% year-over-year to $2.95 billion for the nine-month period, highlighting the segment's continued strength.
3Income from operations for the nine months increased by 20.5% to $1.04 billion, demonstrating effective operational leverage.
4Diluted earnings per share (EPS) for the nine-month period reached $9.99, a substantial increase from $8.05 in the prior year.
5The company generated $826.0 million in net cash from operating activities for the nine months, reflecting strong cash-generating capabilities.
6Share repurchases totaled $979.2 million for the nine-month period, indicating a commitment to returning capital to shareholders.
7The company maintained compliance with its financial covenants, with a debt to Adjusted EBITDA ratio of 0.65 as of September 30, 2025.

IDEXX LABORATORIES INC /DE Quarterly Report for Q3 Ended Sep 30, 2025

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions